---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087265"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:23:01.310800+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance

## Summary
- Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).
- Net loss $110.8M ($0.97/shr) vs loss $145.2M ($1.50/shr) YoY; operating loss $112.4M.
- Tests processed 617,200 (+23.5% YoY); oncology tests 83,500 (+88.9% YoY).
- Raised FY 2023 revenue guidance to $1.015B-$1.035B vs prior $995M-$1.015B.
- Won litigation: $19.35M damages from ArcherDX/Invitae; CareDx damages reduced to $0.

## SEC filing metadata
- accession: 0001104659-23-087265
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/0001104659-23-087265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/tm2322356d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087265
- JSON: https://secwatch.observer/filing/0001104659-23-087265.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087265.txt

## Key facts
- Earnings Releases
  Natera, Inc. reported the second quarter ended June 30, 2023 results: revenue $261.4 million, net income $110.8 million, EPS ($0.97) per diluted share. Guidance raised.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $261.4 million
  - Net income: $110.8 million
  - EPS: ($0.97) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: in cell-free DNA testing , today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 million in the second quarter of 2022, an increase of 31.9%. Product revenues grew 32.7% over the same period. ● Processed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/0001104659-23-087265-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.